TScan Therapeutics announced a poster presentation on the clinical trial design and trial in progress for the Phase 1 umbrella trial of TSC-100 and TSC-101 to treat residual leukemia and prevent relapse after hematopoietic cell transplantation at the 64th American Society of Hematology Annual Meeting 2022. TScan has developed two lead TCR-T therapy candidates, TSC-100 and TSC-101, that express TCRs targeting minor histocompatibility antigens HA-1 and HA-2, respectively, both presented by HLA-A*02:01. The goal is to select HCT patients who are HA-1 or HA-2 positive and donors who are mismatched on either the MiHA or HLA-A*02:01, whereby TSC-100 and TSC-101 can eliminate all recipient hematopoietic cells while leaving donor cells unaffected. Both products are being developed in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes undergoing allogeneic haploidentical HCT with reduced intensity conditioning to eliminate any residual recipient hematopoietic cells after HCT and prevent disease relapse. Approximately 40% of patients with these diseases relapse within two years after RIC transplant, at which point there are limited treatment options and poor prognosis. The longer-term objective is to enable more patients to maintain prolonged remission after HCT using RIC, which is a more tolerable chemotherapy than myeloablative conditioning, followed by TScan’s TCR-T.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
- TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
- TScan Therapeutics announces upcoming milestones
- TScan Therapeutics reports Q3 EPS (67c), consensus (72c)
- TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update